Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

LUNAR Study Investigators

doi:10.1016/S1470-2045(23)00344-3

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

LUNAR Study Investigators

Baptist Health South Florida

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1002-1017
Number of pages	16
Journal	The Lancet Oncology
Volume	24
Issue number	9
DOIs	https://doi.org/10.1016/S1470-2045(23)00344-3
State	Published - Sep 2023

ASJC Scopus Subject Areas

Oncology

Access to Document

10.1016/S1470-2045(23)00344-3

Cite this

LUNAR Study Investigators (2023). Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. The Lancet Oncology, 24(9), 1002-1017. https://doi.org/10.1016/S1470-2045(23)00344-3

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. / LUNAR Study Investigators.
In: The Lancet Oncology, Vol. 24, No. 9, 09.2023, p. 1002-1017.

Research output: Contribution to journal › Article › peer-review

LUNAR Study Investigators 2023, 'Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study', The Lancet Oncology, vol. 24, no. 9, pp. 1002-1017. https://doi.org/10.1016/S1470-2045(23)00344-3

@article{3348bd694005401fa0da3aeb386749c6,

title = "Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study",

author = "{LUNAR Study Investigators} and Ticiana Leal and Rupesh Kotecha and Rodryg Ramlau and Li Zhang and Janusz Milanowski and Manuel Cobo and Jaromir Roubec and Lubos Petruzelka and Libor Havel and Sujith Kalmadi and Jeffrey Ward and Zoran Andric and Thierry Berghmans and Gerber, {David E.} and Goetz Kloecker and Rajiv Panikkar and Joachim Aerts and Angelo Delmonte and Miklos Pless and Richard Greil and Christian Rolfo and Wallace Akerley and Michael Eaton and Mussawar Iqbal and Corey Langer",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Ltd",

year = "2023",

month = sep,

doi = "10.1016/S1470-2045(23)00344-3",

language = "English",

volume = "24",

pages = "1002--1017",

journal = "The Lancet Oncology",

issn = "1470-2045",

number = "9",

}

TY - JOUR

T1 - Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR)

T2 - a randomised, open-label, pivotal phase 3 study

AU - LUNAR Study Investigators

AU - Leal, Ticiana

AU - Kotecha, Rupesh

AU - Ramlau, Rodryg

AU - Zhang, Li

AU - Milanowski, Janusz

AU - Cobo, Manuel

AU - Roubec, Jaromir

AU - Petruzelka, Lubos

AU - Havel, Libor

AU - Kalmadi, Sujith

AU - Ward, Jeffrey

AU - Andric, Zoran

AU - Berghmans, Thierry

AU - Gerber, David E.

AU - Kloecker, Goetz

AU - Panikkar, Rajiv

AU - Aerts, Joachim

AU - Delmonte, Angelo

AU - Pless, Miklos

AU - Greil, Richard

AU - Rolfo, Christian

AU - Akerley, Wallace

AU - Eaton, Michael

AU - Iqbal, Mussawar

AU - Langer, Corey

PY - 2023/9

Y1 - 2023/9

UR - http://www.scopus.com/inward/record.url?scp=85169039347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85169039347&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(23)00344-3

DO - 10.1016/S1470-2045(23)00344-3

M3 - Article

C2 - 37657460

AN - SCOPUS:85169039347

SN - 1470-2045

VL - 24

SP - 1002

EP - 1017

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 9

ER -

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

ASJC Scopus Subject Areas

Access to Document

Other files and links

Cite this